The estimated Net Worth of Thomas Mc Naughton is at least 38.9 千$ dollars as of 15 June 2018. Thomas Naughton owns over 2,500 units of Harvard Bioscience stock worth over 38,867$ and over the last 16 years Thomas sold HBIO stock worth over 0$.
Thomas has made over 2 trades of the Harvard Bioscience stock since 2016, according to the Form 4 filled with the SEC. Most recently Thomas bought 2,500 units of HBIO stock worth 11,000$ on 15 June 2018.
The largest trade Thomas's ever made was buying 5,000 units of Harvard Bioscience stock on 20 May 2016 worth over 7,800$. On average, Thomas trades about 536 units every 54 days since 2008. As of 15 June 2018 Thomas still owns at least 13,734 units of Harvard Bioscience stock.
You can see the complete history of Thomas Naughton stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON, MA, 01746.
Over the last 21 years, insiders at Harvard Bioscience have traded over 10,145,146$ worth of Harvard Bioscience stock and bought 754,658 units worth 2,380,232$ . The most active insiders traders include Earl R Lewis、Bertrand Loy、David Green. On average, Harvard Bioscience executives and independent directors trade stock every 43 days with the average trade being worth of 182,054$. The most recent stock trade was executed by James W Green on 13 June 2024, trading 10,000 units of HBIO stock currently worth 29,100$.
harvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.
Harvard Bioscience executives and other stock owners filed with the SEC include: